Weight‑Loss Medications Linked to Higher Fracture Risk, New Study Finds

In recent years, medications such as Ozempic, Wegovy, and Mounjaro have become household names for their impressive ability to help people lose weight and control blood sugar. While these drugs—glucagon‑like peptide‑1 (GLP‑1) receptor agonists and dual agonists—have earned praise for their metabolic benefits, a new study has raised concerns about their long‑term impact on bone and joint health. The research, published in the peer‑reviewed journal ScienceAlert, suggests that people using semaglutide (the active ingredient in Ozempic and Wegovy) or tirzepatide (found in Mounjaro and Zepbound) may face a higher risk of fractures and other musculoskeletal problems.

What the Study Revealed

The investigators analyzed data from over 120,000 adults who had been prescribed GLP‑1 agonists or dual agonists for weight management or type 2 diabetes. By comparing these patients to control groups—those on other weight‑loss drugs or no medication at all—the researchers identified a statistically significant increase in several bone and joint conditions among the drug users.

The most striking findings were:

• Higher fracture rates—particularly in the hip, spine, and wrist.
• Increased incidence of osteoarthritis—especially in weight‑bearing joints such as the knees and hips.
• More frequent reports of joint pain and stiffness, often leading to reduced mobility.
• Elevated risk of osteopenia and osteoporosis diagnoses over the follow‑up period.

These associations persisted even after adjusting for age, sex, body mass index, baseline bone density, and other risk factors. The authors caution that the study design cannot prove causation, but the findings warrant close attention from clinicians and patients alike.

How GLP‑1 Drugs Might Affect Bones

GLP‑1 agonists work by mimicking the hormone GLP‑1, which stimulates insulin secretion and slows gastric emptying. While their primary targets are the pancreas and gastrointestinal tract, the drugs also influence other tissues, including bone. Several mechanisms have been proposed to explain the observed bone‑health effects:

• Altered calcium metabolism—GLP‑1 receptors are present on osteoblasts and osteoclasts, the cells that build and break down bone. Chronic activation may shift the balance toward bone resorption.
• Reduced vitamin D activation—some animal studies suggest GLP‑1 agonists can lower the activity of the enzyme that converts vitamin D to its active form, potentially compromising bone mineralization.
• Weight loss‑related changes—rapid or significant weight loss can decrease mechanical loading on bones, accelerating bone loss, especially in individuals with pre‑existing low bone density.
• Hormonal interplay—GLP‑1 therapy can influence sex hormone levels, which are critical regulators of bone turnover.

While the exact pathways remain under investigation, the convergence of these factors likely contributes to the increased fracture risk noted in the study.

What Patients and Doctors Should Know

For many people, the benefits of GLP‑1 agonists—weight loss, improved glycemic control, and reduced cardiovascular risk—outweigh potential bone concerns. However, the new evidence underscores the importance of a balanced approach:

1. Screen for bone health—Patients starting GLP‑1 therapy, especially those over 50, with a history of fractures, or with low baseline bone density, should discuss bone density testing (DEXA scan) with their provider.